ZNF233

Across TCGA pan-cancer cohorts, ZNF233 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF233 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF233 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF233 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LUSC, and BLCA are the cancer types where ZNF233 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.382	0.772	.001	45	view →
LUSC	OS	Median	All	0.179	0.729	<.001	18	view →
BLCA	DFS	Median	All	0.121	0.594	.009	15	view →
KIRC	OS	Median	All	0.244	0.810	.008	12	view →
UCEC	DFS	Median	All	1.000	0.622	.013	12	view →
LUAD	OS	Median	All	0.286	0.702	.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF233–HNSC (OS)

Open the HNSC breakdown →